Brian Feagan.

Brian Feagan, Director of Robarts Clinical Trials at Robarts Research Institute at The University of Western Ontario. Dr . Feagan coordinated the research trial and is an author on the analysis. It’s just a safer, even more effective treatment method. The alternative strategy, called ‘top-down’ therapy, employs early use of immune-suppressing drugs combined with an antibody in order to address the disease from the start. Symptom-treating steroids may never be needed. The two-year study was conducted at analysis centres in Belgium, Holland, and Germany and involved 129 subjects with active Crohn’s disease.

Other articles from category "Uncategorized":

Random articles